LIVE from EHFG: New Paths to Personalised Medicine: How Medicine’s Adaptive Pathways to Patients (MAPPs) and Breakthrough Designation will impact Patients

September 30th, 18.00-19.30 CET

Organised by European Alliance of Personalised Medicine (EAPM), European Federation of Pharmaceutical Industries and Associations (EFPIA) and Vital Transformation with the support of AstraZeneca.

In a moderated discussion with experts, the audience and live participation from the public via the Twitter hashtag #EHFG2015, the panel investigated what the potential long-term implications of new models for personalised medicines are, and what their adoption means for regulators, payers, patients and society as a whole.


SONY DSC stanimir100x100
Chris Hoyle,
Director, Health Economics & Payer Analytics (Oncology),
Stanimir Hasurdjiev,
General Secretary,
Patient Access Partnership
carole-longson-100x100 gordon-mcvie100x100
Carole M Longson,
Director Centre for Health Technology Evaluation,
Gordon McVie,
Senior Consultant,
European Institute of Oncology,
Secretary European Alliance for Personalised Medicine (EAPM)
Amy Miller 100x100 Duane-sq
Amy M Miller,
Executive VP,
Personalized Medicine Coalition
Duane Schulthess,
Managing Director,
Vital Transformation

Click to view clips from individual speakers: 


This session is organised in partnership with: